This study will determine the efficacy of etanercept in children with systemically active systemic onset juvenile rheumatoid arthritis (SOJRA).
Phase 3 Safety and Efficacy Study of Etanercept (Enbrel®) In Children with Systemic Onset Juvenile Rheumatoid Arthritis
Arthritis, Juvenile Rheumatoid
Treatment, Placebo Control, Safety/Efficacy Study
Eligibility & Criteria
Ages Eligible for Study: 2 Years – 18 Years, Genders Eligible for Study: Both Criteria – Patients must have systemic features of SOJRA – Active joints – Abnormal labs; albumin, platelets, Hgb, CRP – Stable dose of Prednisone – Stable dose or Off Methotrexate for 4 weeks – Blinded, placebo controlled
For additional information regarding investigative sites for this trial, contact the Amgen Call Center at 1-866-57AMGEN (1-866-572-6436)